Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Sponsor
Sanofi-Aventis Australia
Administration route
Intramuscular injection
Vaccine group
Combination vaccines
Description:
Registered as a booster in people aged ≥4 years.
dTpa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine (reduced antigen formulation)
Each 0.5 mL monodose vial or pre-filled syringe contains:
- ≥2 IU diphtheria toxoid
- ≥20 IU tetanus toxoid
- 2.5 µg pertussis toxoid
- 5 µg filamentous haemagglutinin
- 3 µg pertactin
- 5 µg pertussis fimbriae types 2 and 3
- 29 D-antigen units inactivated poliovirus type 1 (Mahoney)
- 7 D-antigen units inactivated poliovirus type 2 (MEF-1)
- 26 D-antigen units inactivated poliovirus type 3 (Saukett)
- 0.33 mg aluminium as aluminium phosphate
- 0.6% v/v phenoxyethanol
Also contains traces of:
- formaldehyde
- glutaraldehyde
- polysorbate 80
- polymyxin
- neomycin
- streptomycin
For Product Information and Consumer Medicine Information about Adacel Polio visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.
Page history
Last updated
Last reviewed
Related diseases